ProCE Banner Activity

CME

Partnering With Patients in the Treatment of Psoriatic Arthritis

Multimedia
In this video module, 2 patients join rheumatologist Jonathan Scott Coblyn, MD, to share their perceptions and experience with psoriatic arthritis while Dr. Coblyn provides expert commentary with an emphasis on patient engagement in the management of psoriatic arthritis.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: March 15, 2017

Expiration: June 14, 2018

No longer available for credit.

Share

Faculty

Jonathan Scott Coblyn

Jonathan Scott Coblyn, MD

Associate Professor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director of Rheumatology
Division of Rheumatology
Department of Medicine
Brigham and Womens Hospital
Boston, Massachusetts

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Target Audience

This program is intended for rheumatologists, dermatologists, and other healthcare professionals caring for patients with psoriatic arthritis.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement screening procedures to improve early detection and timely diagnosis of PsA in patients with psoriasis
  • Incorporate patient perceptions and preferences in developing comprehensive treatment plans for PsA
  • Apply a multidisciplinary approach to the management of common PsA-associated comorbidities, including depression

Faculty Disclosure

Primary Author

Jonathan Scott Coblyn, MD

Associate Professor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director of Rheumatology
Division of Rheumatology
Department of Medicine
Brigham and Womens Hospital
Boston, Massachusetts

Jonathan Scott Coblyn, MD, has disclosed that he has received consulting fees from CVS Pharmacy.

Staff Disclosure

Staff

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 15, 2017, through June 14, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve physicians’ competence in understanding the patient’s perception of their disease and increasing the patient’s involvement in treatment decisions in order to improve disease management and quality of life for patients with psoriatic arthritis.